Fortis Q2 net profit falls 2.5% on higher expenses, lower exceptional gain
Fortis Healthcare moved higher in a quarterly results development for Q2FY27.
· BS Companies
Fortis Healthcare's Q2FY27 net profit declined to ₹320 crore as expenses rose, while revenue grew 17 per cent to ₹2,735 crore, driven by hospitals and…
Key facts
- Period
- Q2FY27
The analysis
Fortis Healthcare reported ₹320 crore and ₹2,735 crore for Q2FY27, with movement of 17% and 2.5% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +3.7% on the day at ₹819.80, and has returned -11.4% over three months. It sits 20% below its 52-week high. The pharma & healthcare sector has moved +1.1% over the same period, so Fortis Healthcare is running 12.5 points behind its peers.
For Fortis Healthcare, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Fortis Healthcare (FORTIS), in Pharma & Healthcare.
- Over three months: Fortis Healthcare -11.4% against Pharma & Healthcare +1.1% (12.5 points behind).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Fortis HealthcareFORTIS · Pharma & Healthcare | ₹819.80 | +3.7% | +7.3% | -11.4% | -19.6% | 1.1× | — |
Pharma & Healthcare
1M +3.9% · 3M +1.1%
Fortis Healthcare
Prices as of 5 Nov 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Q2 Results Live Updates: LG Electronics, Bharti Airtel, Abbott India, Astral, Bharat Forge, Berger Paints, Emami, Fortis Healthcare Earnings In Focus
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Biocon share price rises nearly 6% despite 52% dip in Q2 profit
Glenmark Pharma Q2 revenue falls 30% to ₹4,247 crore, profit down 57%
Apollo's Bangladesh patient revenue nears pre-crisis peak of ₹450 crore